Natick, United States
PIC Therapeutics is a pioneering biotechnology company committed to transforming cancer treatment by developing innovative therapeutics centered on RNA translation modulation. Founded in 2016, PIC Therapeutics leverages the groundbreaking research of Dr. Gerhard Wagner of Harvard Medical School, focusing on the interplay of eukaryotic translation initiation factors.
Under the leadership of Dr. Kathy Bowdish, PIC Therapeutics is at the forefront of creating small molecule precision therapeutics, targeting the critical "master switch" of cancer signaling pathways. Their unique approach modulates the Pre-Initiation Complex (PIC) to selectively inhibit oncogene protein production, potentially impacting multiple oncogenic drivers for a robust therapeutic effect.
The company, based in the United States, secured a $35.00M Series A investment in October 2022, with notable investors including Advent Life Sciences, OrbiMed, and Lumira Ventures. With a focus on health care and wellness, they stand as a compelling investment opportunity in the fight against cancer.
